Georgetown Lombardi Comprehensive Cancer Center | Strategic Alliance Partners

May 10, 2019

Louis M. Weiner, MD, director of the Georgetown Lombardi Comprehensive Cancer Center, discusses the criteria required to become an NCI-designated cancer center.

April 08, 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses HER2 amplification in colorectal cancer (CRC).

March 07, 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the importance of broad molecular profiling in patients with gastrointestinal cancers.

March 06, 2019

Benjamin Weinberg, MD, discusses frontline standards of care in metastatic pancreatic cancer and highlights emerging agents targeting the stroma.

March 05, 2019

John L. Marshall, MD, chief, Division of Hematology/Oncology, Medstar Georgetown University Hospital director, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown-Lombardi Comprehensive Cancer Center, discusses personalized chemotherapy in the treatment of patients with colorectal cancer.

March 05, 2019

Aiwu Ruth He, MD, PhD, discusses the newly crowded treatment landscape of hepatocellular carcinoma and highlights next steps for research.

March 05, 2019

John L. Marshall, MD, discusses the current and future scope of metastatic colorectal cancer.

February 26, 2019

Benjamin Weinberg, MD, assistant professor of medicine, Division of Hematology and Oncology, Lombardi Comprehensive Cancer Center, Georgetown University, discusses the use of FOLFIRINOX in older patients with metastatic pancreatic cancer.

January 29, 2019

Subha Madhavan, PhD, discusses the role of data science and informatics in bringing novel clinical study designs to the field of oncology.

January 04, 2019

Patrick M. Forde, MBBCh, discusses the future of immunotherapy in early-stage non–small cell lung cancer.

January 03, 2019

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

December 17, 2018

Michael J. Pishvaian, MD, PhD, discusses the impact of immunotherapy in the treatment landscape of hepatocellular carcinoma.

December 01, 2018

Stephen Liu, MD, discusses ongoing developments in the treatment of patients with ALK-positive NSCLC.

November 02, 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the combination of atezolizumab (Tecentriq) and bevacizumab (Avastin) in patients with hepatocellular carcinoma.

August 26, 2018

Stephen Liu, MD, provided an enhanced understanding of oncogenic drivers such as EGFR and ALK in patients with NSCLC, sequencing strategies, and the potential application of immunotherapy in later lines of therapy.

May 03, 2018

Immunotherapy has arrived in the gastrointestinal cancer landscape, and while not all patients will benefit from these agents, those who do are likely to have long-lasting responses, explained John L. Marshall, MD.

March 01, 2018

Claudine Isaacs, MD, professor, medical director, Fisher Center for Familial Cancer Research, co-director, Breast Cancer Program, Georgetown University/Lombardi Cancer Center, discusses antibody drug conjugates in the treatment of patients with triple-negative breast cancer.

March 01, 2018

Michael J. Pishvaian, MD, discusses expanded testing for biomarkers, using liquid biopsies to predict response to treatment, and the importance of identifying increasingly specific subsets of GI cancers to make treatment decisions.

February 27, 2018

Aiwu Ruth He, MD, PhD, associate professor of medicine, Georgetown-Lombardi Comprehensive Cancer Center, discusses the future of precision medicine in gastrointestinal malignancies.

February 22, 2018

Pembrolizumab (Keytruda) induced responses in more than one-fifth of patients with recurrent thymic carcinoma who had progressed following 1 or more lines of chemotherapy.